US20140011835A1

US20140011835A1 - [1,10]-phenanthroline derivatives for the treatment of neurodegenerative or haematological diseases

Info

Publication number: US20140011835A1
Application number: US14/027,225
Authority: US
Inventors: Ana Martinez Gil; Ana Castro Morera; Miguel Medina Padilla; Jorge Sanchez-Quesada; Mercedes Alonso Cascon; Laura Rubio Arrieta; Esther Garcia Palomero; Paola Usan Egea
Original assignee: Noscira SA
Current assignee: Noscira SA
Priority date: 2007-06-11
Filing date: 2013-09-15
Publication date: 2014-01-09
Also published as: MX2009013482A; US20100240692A1; AU2008263897A1; US8592446B2; UY31143A1; CL2008001719A1; WO2008152068A3; EP2002863A1; AR066956A1; EP2170464A2; TW200914016A; WO2008152068A2; CN101801461A; RU2009148821A; JP2010529167A; CA2690455A1

Abstract

The present invention relates to a new family of [1,10]-phenantroline derivatives of formula (I), which are useful for the treatment or prophylaxis of a neurodegenerative or hematological disease or condition, their use as a medicament, especially for treating a neurodegenerative or hematological disease or condition, and a pharmaceutical composition comprising the compounds.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. patent application Ser. No. 12/664,130 filed on Dec. 11, 2009, which is a U.S. national phase under the provisions of 35 U.S.C. §371 of International Patent Application No. PCT/EP08/57319 filed on Jun. 11, 2008, which in turn claims priority of European Patent Application No. 07380167.2 filed on Jun. 11, 2007. The disclosures of U.S. patent application Ser. No. 12/664,130, International Patent Application No. PCT/EP08/57319, and European Patent Application No. 07380167.2 are hereby incorporated herein by reference in their respective entireties, for all purposes.

FIELD OF THE INVENTION

The present invention relates to the use of some [1,10]-phenanthroline derivatives for the treatment and/or prophylaxis of a neurodegenerative or haematological disease or condition, particularly Alzheimer's disease (AD). Additionally, there is provided new [1,10]-phenanthroline derivatives, a process for preparing such compounds and pharmaceutical compositions comprising them.

BACKGROUND OF THE INVENTION

AD and Parkinson's disease (PD) are the most frequent progressive neurodegenerative diseases affecting millions of people in the world. Because a significant percentage of patients share common clinical and pathological symptoms from both entities, this seems to indicate the existence of a common pathological mechanism.
Oxidative stress is known to be involved in many diseases, including atherosclerosis, Parkinson's disease and AD, and may be also important in ageing.
Reactive oxygen species (ROS), such as oxygen radical superoxide (02) or hydrogen peroxide (H₂O₂), are produced during normal metabolic processes and perform several useful functions (Reactive oxygen species and the central nervous system, Halliwell B., J. Neurochem.; 1992, 59 859: 1609-1623). Cells are provided with several mechanisms to control levels of these oxidative agents, for instance, superoxide dismutase (SOD), glutathione or vitamin E. In normal physiological conditions, a balance between ROS and these anti-oxidative mechanisms exists. An excessive production of ROS and a loss of efficiency of the anti-oxidative defences can lead to cellular oxidative stress and thus to pathological conditions in cells and provoke tissue damage. This event seems to occur more dramatically in neurons, because of their high rate of metabolic activity, and thus seems to be related to a series of degenerative processes, diseases and syndromes, for example, AD, PD, amyotrophic lateral sclerosis (ALS) and schizophrenia (Glutathione, oxidative stress and neurodegeneration, Schulz et al., Eur. J. Biochem.; 2000, 267, 4904-4911). Also other diseases or pathological conditions have been related to oxidative stress, such as Huntington's Disease (Oxidative damage in Huntington's disease, Segovia J. and Pérez-Severiano F, Methods Mol. Biol.; 2004; 207: 321-334), brain injuries, such as stroke and ischemia, (Oxidative Stress in the Context of Acute Cerebrovascular Stroke, El Kossi et al., Stroke; 2000; 31: 1889-1892), diabetes (Oxidative stress as a therapeutic target in diabetes: revisiting the controversy, Wiernsperger N F, Diabetes Metab.; 2003; 29, 579-85), multiple sclerosis (The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy, Gilgun-Sherki Y. et al., J. Neurol.; 2004; 251 (3): 261-8), epilepsy (Oxidative injury in epilepsy: potential for antioxidant therapy?, Costello D. J. and Delanty N., Expert. Rev. Neurother.; 2004; 4(3):541-553), atherosclerosis (The oxidative stress hypothesis of atherogenesis, Iuliano L., Lipids; 2001; 36 suppl: S41-44), Friedreich's Ataxia (Oxidative stress mitochondrial dysfunction and cellular stress response in Friedreich's ataxia, Calabrese et al., J. Neurol. Sci.; 2005) and heart failure (Oxygen, oxidative stress, hypoxia and heart failure, Giordano F. J., J. Clinic. Invest.; 2005; 115 (3): 500-508). Treatments that lead to an enhancement of the anti-oxidative mechanisms may slow down the progression of some of the mentioned diseases.
Another type of cellular stress is the endoplasmic reticulum (ER) stress. The ER is an intracellular organelle represented by an extensive network formed by cisternae and microtubules and which extends from the nuclear envelope to the cell surface in all eukaryotic cells. ER plays several vital functions: the rough ER is the place for protein synthesis and postranslational changes for the correct folding of proteins, ER is the common transport route to deliver proteins to their proper destination within the cell and it is also a Ca²⁺ reservoir. Disturbances in the function of ER lead to accumulation of unfolded proteins within the ER, inducing a condition generally referred to as ER stress. These disturbances can be caused not only by biochemical imbalance but also by disturbance in the ER Ca²⁺ homeostasis. Some studies (Glycogen synthase kinase 3β (GSK3β) mediates 6-hydroxydopamine-induced neuronal death, Chen et al., FASEB J. 2004; 18(10):1162-4) demonstrate that ER stress activates the enzyme glycogen synthase kinase 3β, an enzyme involved in the neurodegenerative process occurred in patients with AD.
The catecholaminergic neurotoxin 6-hydroxydopamine (6-OHDA) is formed endogenously in patients suffering from Parkinson's disease. 6-OHDA has two ways of action: it easily forms free radicals and it is a potent inhibitor of the mitochondrial respiratory chain complexes I and IV. 6-hydroxydopamine (6-OHDA) models are used to produce a broad spectrum of neurochemical and behavioural deficits characterising DA degeneration in humans, specially for PD (e.g. Glinka Y et al, “Mechanism of 6-hydroxydopamine neurotoxicity”, J Neural Transm Suppl. 1997; 50:55-66; Willis G L et al, “The implementation of acute versus chronic animal models for treatment discovery in Parkinson's disease” Rev Neurosci. 2004; 15(1):75-87).
A common sign of neurodegenerative diseases is the accumulation and deposits of misfolded proteins which affect several signalling pathways which lead finally to neuronal death. Some authors (ER stress and neurodegenerative diseases, Lindholm et al., Cell Death and Differentiation; 2006; 13: 385-392) consider that ER stress is related to several neurodegenerative diseases such as, PD, AD, ALS, and transmissible spongiform encephalopaties (TSEs).
In view of the above, an interesting approach for developing new pharmaceutical compounds for treating neurodegenerative diseases may be designing compounds which inhibit cellular oxidative stress.
Amyloid beta (Aβ) is a peptide that is the main constituent of amyloid plaques in the brains of AD patients. Similar plaques appear in some variants of Lewy body dementia and in inclusion body myositis, a muscle disease. Aβ also forms aggregates coating cerebral blood vessels in cerebral amyloid angiopathy.
Aβ is formed after sequential cleavage of the amyloid precursor protein (APP) by the β- and γ-secretases. Either Aβ₄₂or Aβ₄₀are produced depending on where the cleavage occurs. APP is a transmembrane glycoprotein. Autosomal-dominant mutations in APP cause hereditary early-onset AD, likely as a result of altered proteolytic processing. Increases in total Aβ levels have been implicated in the pathogenesis of both familial and sporadic AD [The American Journal of Pathology; Lue, L; 155(3):853-662 (1999)].
According to the “amyloid hypothesis”, accepted by the majority of researchers, the plaques are responsible for the pathology of AD. Intra-cellular deposits of tau protein are also seen in the disease, and may also be implicated. The oligomers that form on the amyloid pathway, rather than the mature fibrils, may be the cytotoxic species.
Thus, the development of inhibitors of amyloid beta secretion are a current strategy to find treatments for diseases in which amyloidosis is involved, such as AD, PD, Huntington's disease, TSEs, Prion diseases, Creutzfeldt-Jakob disease and Bovine spongiform encephalopathy.
On the other hand, iron chelators are used to treat some kinds of haematological diseases, such as thalassaemia, anaemia, aplastic anaemia, myelodysplastic syndrome, diabetes, Diamond-Blackfan anaemia, sickle cell disease, hematologic disorders which require regular red cell transfusions, iron-induced cardiac dysfunction, and iron-induced heart failure.
Metals such as iron are capable of redox cycling in which a single electron may be accepted or donated by the metal. This action catalyzes reactions that produce reactive radicals and can produce reactive oxygen species. The most important reactions are probably Fenton's reaction and the Haber-Weiss reaction, in which hydroxyl radical is produced from reduced iron and hydrogen peroxide. The hydroxyl radical then can lead to modifications of amino acids (e.g. meta-tyrosine and ortho-tyrosine formation from phenylalanine), carbohydrates, initiate lipid peroxidation, and oxidize nucleobases. Most enzymes that produce reactive oxygen species contain one of these metals. The presence of such metals in biological systems in an uncomplexed form (not in a protein or other protective metal complex) can significantly increase the level of oxidative stress. Therefore, it is desirable that chelating ligands for the treatment of conditions according to the invention, show a preference towards Fe(II) rather than Fe(III).
Iron chelators deferoxamine and deferiprone, have been used in humans since the 1970s and the late 1980s, respectively, and lately a new drug, deferasirox has been used in humans. Deferoxamine has proven efficient in thalassemia major, sickle cell disease and other hematologic disorders for which hematologic disorders, but can only be administered subcutaneously [Blood; Neufeld, E. L., 107(9): 3436-3441 (2006)]. Deferasirox, approved in the US for chronic iron overload due to blood transfusions, has shown moderate to good success [Hematology; Cohen, A. R., 42-47 (2006)]. Combination therapy with deferiprone and deferoxamine is also being used.
However, side effects have been associated with the use of these drugs; deferiprone often causes gastrointestinal symptoms, erosive arthritis, neutropenia and in some cases agranulocytosis; deferiprone therapy requires weekly complete blood count and ancillary supplies for infusion, so close monitoring is required; deferoxamine presents gastrointestinal symptoms and joint pain and deferasirox is costly. Therefore there still remains a need for additional therapeutic iron chelators for use in these hematological diseases, produced and used with low cost and reduced side effects.
It is well known that phenanthroline derivatives exhibit good iron chelating properties. Some phenanthroline derivatives are shown in patent PL76345. It would be highly recommended to find new phenanthroline derivatives which can show improved properties in chelating iron metal in order to provide an enhanced capability for treating the haematological mentioned diseases.

SUMMARY OF THE INVENTION

The authors of the present invention have found a new family of compounds, namely [1,10]-phenanthroline derivatives, defined by formula (I) as detailed below, which encompasses the properties of protecting from oxidative stress, particularly from hydrogen peroxide-cell death and 6-hydroxydopamine-cell death, having a neuroprotective effect against Aβ toxicity, and inhibiting Aβ secretion. Surprisingly, the inventors have found that the compounds of the invention are capable of crossing the brain blood bather. They may thus be useful for the treatment or prophylaxis of neurodegenerative diseases or conditions. In addition, these compounds are characterized for acting as specific iron (II) chelators and therefore they could also be used to treat haematological diseases.
Therefore, according to a first aspect, the present invention is directed to the use of a compound of formula (I):
wherein R¹is selected from —S—R³, —O—R⁴and halogen;
R⁷is selected from —CH═N—OR⁸or —CHO;
R³and R⁴are independently selected from the group consisting of C₁-C₆alkyl, C₆-C₁₅aryl and heteroaryl, optionally substituted by C₁-C₆alkyl, C₆-C₁₅aryl, halogen, preferably by 1 to 6 halogen atoms, more preferably 1 to 3, —(C═O)NR⁵R⁶, —(C═O)OR⁵, C₁-C₆alkoxy and/or —NR⁵R⁶,
R⁵and R⁶being independently selected from hydrogen and C₁-C₆alkyl,
R⁸is selected from hydrogen and C₁-C₆alkyl;
or any salt or solvate or stereoisomer or tautomer thereof,
in the preparation of a medicament for the treatment or prophylaxis of a neurodegenerative or haematological disease or condition.
Thus an aspect of the invention are the compounds of formula (I) as defined above for the treatment or prophylaxis of a neurodegenerative or haematological disease or condition.
The compounds of formula (I) may be used in biological assays wherein beta-amyloid secretion needs to be modulated. Therefore, in another aspect, the invention refers to the use of a compounds of formula (I) as defined above, or any salt or solvate thereof, as reagent for biological assays, preferably as a reactive for pharmacokinetic assays, blood brain barrier crossing assays, chelation assays, for essays on protection against hydrogen peroxide-induced cell death, protection against 6-OHDA-induced cell death, neuroprotection against Aβ toxicity and inhibiton of beta-amyloid secretion.
A further aspect of the invention refers to a method of treating or preventing a disease or condition, said method comprises administering to a patient in need of such a treatment a therapeutically effective amount of at least one compound of formula (I) as defined above, its salts, solvates, stereoisomers or tautomers thereof, or a pharmaceutical composition thereof.
According to a further aspect, the present invention is directed to a compound of formula (I)
wherein R¹is selected from —S—R³, —O—R⁴and halogen;
R⁷is selected from —CH═N—OR⁸or —CHO;
R³and R⁴are independently selected from the group consisting of C₁-C₆alkyl, C₆-C₁₅aryl and heteroaryl, optionally substituted by C₁-C₆alkyl, C₆-C₁₅aryl, halogen, —(C═O)NR⁵R⁶, —(C═O)OR⁵, C₁-C₆alkoxy and/or —NR⁵R⁶,
R⁵and R⁶being independently selected from hydrogen and C₁-C₆alkyl,
R⁸is selected from hydrogen and C₁-C₆alkyl;
or any salt or solvate or stereoisomer or tautomer thereof,
with the proviso that when R¹is Cl, then R⁷is not —CHO.
Another aspect of the present invention refers to a pharmaceutical composition comprising at least one compound of formula (I) as defined above, its salts or solvates or stereoisomers or tautomers thereof, and at least one pharmaceutically acceptable carrier.
According to a further aspect, the present invention is directed to a compound of formula (I) as defined above, its salts, solvates or stereoisomers or tautomers thereof, for use as a medicament.
According to a further aspect, the present invention is directed to a process for the synthesis of the compounds of formula I, its salts or solvates or stereoisomers or tautomers thereof.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is an absorbance spectrum of

compounds

4, 7, 8 and 10 in absence and presence of Fe(III). PBS 10 mM, pH 7.4. Concentration of ligand and Fe(III), 200 μM.

FIG. 2 is an absorbance spectrum of the complex Fe(II)-Compound 4. Concentration of Fe(II) and

Compound

4, 200 μM, PBS 10 mM, pH 8.

FIG. 3 is an absorbance spectrum of the complex Fe(II)-Compound 7. Concentration of Fe(II) and

Compound

7, 400 μM, PBS 10 mM, pH 8.

FIG. 4 is an absorbance spectrum of the complex Fe(II)-Compound 8. Concentration of Fe(II) and

Compound

8, 200 μM, PBS 10 mM, pH 7.4.

FIG. 5 is an absorbance spectrum of the complex Fe(II)-Compound 10. Concentration of Fe(II) and Compound 10, 100 μM, PBS 10 mM, pH 7.4.

FIG. 6 depicts the absorbance spectra of the mixture of Cu (II) and each of the quelating ligands (Compound 4, Compound 7, Compound 8). Concentration of Cu(II) and all compounds 200 μM, PBS 10 mM, pH 7.4.

FIG. 7 is the absorbance spectra of the complex Cu(II)-Compound 10. Concentration 200 μM, PBS 10 mM, pH 7.4.

FIG. 8 represents the absorbance spectra of the complex Zn(II)-Compound 4. Concentration 200 μM, PBS 10 mM, pH 7.4.

FIG. 9 shows the absorbance spectra of the complex Zn(II)-Compound 7. Concentration 180 μM, PBS 10 mM, pH 7.4.

FIG. 10 shows the absorbance spectra of the complex Zn(II)-Compound 8. Concentration 100 μM, PBS 10 mM, pH 7.4.

FIG. 11 shows the absorbance spectra of the complex Zn(II)-Compound 10. Concentration 20 μM, PBS 10 mM, pH 7.4.

DETAILED DESCRIPTION OF THE INVENTION

In the above definition of compounds of formula (I) the following terms have the meaning indicated:
“C₁-C₆Alkyl” refers to a linear or branched hydrocarbon chain radical consisting of carbon and hydrogen atoms, containing no unsaturation, having one to six carbon atoms, preferably one to three, and which is attached to the rest of the molecule by a single bond, e.g., methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, n-pentyl, etc.
“C₁-C₆alkoxy” refers to a radical of the formula —OR_awhere R_ais a “C₁-C₆alkyl” radical as defined above, e.g., methoxy, ethoxy, propoxy, etc.
“Halogen” refers to bromo, chloro, iodo or fluoro.
“Aryl” refers to an aromatic hydrocarbon radical having 6 to 15, preferably 6 to 10 carbon atoms such as phenyl or naphthyl.
“Heteroaryl” refers to a stable 3- to 15-membered ring system wherein at least one of the rings is aromatic, and which consists of carbon atoms and from one to five heteroatoms, preferably one to three, selected from the group consisting of nitrogen, oxygen, and sulphur, preferably a 4- to 8-membered ring with one or more heteroatoms, more preferably a 5- or 6-membered ring with one or more heteroatoms, preferably one to three. For the purposes of this invention, the heteroaryl may be a monocyclic, bicyclic or tricyclic ring system, which may include fused ring systems; and the nitrogen, carbon or sulfur atoms in the heteroaryl radical may be optionally oxidised; the nitrogen atom may be optionally quaternized; Examples of such heteroaryles include, but are not limited to thiazol, thiadiazol, benzimidazole, benzothiazole, furan, isothiazole or imidazole,

Uses of Compounds of Formula (I)

According to one embodiment, the invention is directed to the use of a compound of formula (I), wherein

- R¹is selected from —S—R³, —O—R⁴and halogen;
- R⁷is selected from —CH═N—OR⁸or —CHO;
- R³and R⁴are independently a C₁-C₆alkyl, optionally substituted by C₁-C₆alkoxy and/or —NR⁵R⁶,
- R⁵and R⁶being independently selected from hydrogen and C₁-C₆alkyl,
- R⁸is selected from hydrogen and C₁-C₆alkyl.

Within the frame of the present invention, the expression “neurodegenerative disease or condition” means any disease or condition in which neurodegeneration occurs. Such disease or condition includes, but is not limited to, any disease or condition selected from Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), schizophrenia, Huntington's Disease, brain injuries, such as stroke and ischemia, multiple sclerosis, epilepsy, Friedreich's Ataxia, spongiform encephalopaties, amyloidosis, vascular dementia, tauophaties, progressive supranuclear palsy, frontotemporal lobular degeneration, subacute sclerosing panencephalitic parkinsonism, postencephalitic parkinsonism, pugilistic encephalitis, guam parkinsonism-dementia complex, Pick's disease, corticobasal degeneration, frontotemporal dementia, AIDS associated dementia, multiple sclerosis, mood disorders such as depression, schizophrenia and bipolar disorders, promotion of functional recovery post stroke and brain injury, especially traumatic brain injury. In a preferred aspect of the invention, the neurodegenerative disease or condition is Alzheimer's Disease.
Within the frame of the present invention, the expression “haematological disease or condition” means any disease or condition in which disorders of the blood and blood forming tissues occurs. In a preferred embodiment, the haematological disease or condition is selected from thalassaemia, anaemia, aplastic anaemia, Diamond-Blackfan anemia, sickle cell disease, hematologic disorders which require regular red cell transfusions, myelodysplastic syndrome, iron-induced cardiac dysfunction, iron-induced heart failure, and diabetes, more preferably from thalassaemia, anaemia, aplastic anaemia, myelodysplastic syndrome and diabetes.
In a particular aspect, the compound of formula (I) used in the present invention is selected from the following compounds:

4-Methoxy-[1,10]phenanthroline-2-carbaldehyde oxime
4-Chloro-[1,10]phenanthroline-2-carbaldehyde oxime
4-Chloro-[1,10]phenanthroline-2-carbaldehyde
4-Methylsulfanyl-[1,10]phenanthroline-2-carbaldehyde oxime
4-Propylsulfanyl-[1,10]phenanthroline-2-carbaldehyde oxime
4-Ethoxy-[1,10]phenanthroline-2-carbaldehyde oxime
4-Isopropylsulfanyl-[1,10]phenanthroline-2-carbaldehyde oxime
4-(2-Methoxy-ethoxy)-[1,10]phenanthroline-2-carbaldehyde oxime
4-(2-Amino-ethoxy)-[1,10]phenanthroline-2-carbaldehyde oxime
4-(2-Diethylamino-ethoxy)-[1,10]phenanthroline-2-carbaldehyde oxime
4-(2-Methoxy-ethylsulfanyl)-[1,10]phenanthroline-2-carbaldehyde oxime
2-[2-(Hydroxyimino-methyl)-[1,10]phenanthrolin-4-ylsulfanyl]-N,N-dimethyl-acetamide
4-(2,2,2-Trifluoro-ethylsulfanyl)-[1,10]phenanthroline-2-carbaldehyde oxime
[2-(Hydroxyimino-methyl)-[1,10]phenanthrolin-4-ylsulfanyl]-acetic acid methyl ester
4-(Thiazol-2-ylsulfanyl)-[1,10]phenanthroline-2-carbaldehyde oxime
[2-(Hydroxyimino-methyl)-[1,10]phenanthrolin-4-ylsulfanyl]-acetic acid
4-(5-Methyl-thiazol-2-ylsulfanyl)-[1,10]phenanthroline-2-carbaldehyde oxime
4-(5-Methyl-[1,3,4]thiadiazol-2-ylsulfanyl)-[1,10]phenanthroline-2-carbaldehyde oxime
4-([1,3,4]Thiadiazol-2-ylsulfanyl)-[1,10]phenanthroline-2-carbaldehyde oxime
4-Methylsulfanyl-[1,10]phenanthroline-2-carbaldehyde
4-Propylsulfanyl-[1,10]phenanthroline-2-carbaldehyde
4-Propylsulfanyl-[1,10]phenanthroline-2-carbaldehyde oxime
4-Ethoxy-[1,10]phenanthroline-2-carbaldehyde
4-Isopropylsulfanyl-[1,10]phenanthroline-2-carbaldehyde
4-(2-Methoxy-ethoxy)-[1,10]phenanthroline-2-carbaldehyde
4-(2-Diethylamino-ethoxy)-[1,10]phenanthroline-2-carbaldehyde
or its salts, solvates or stereoisomers or tautomers thereof.

The compounds used in the present invention may be used with at least other drug to provide a combination therapy. The at least other drug may form part of the same composition, or be provided as a separate composition for administration at the same time or at different time.
According to a further aspect, the present invention is directed to a method of treating or preventing a neurodegenerative or haematological disease or condition, said method comprises administering to a patient in need of such a treatment a therapeutically effective amount of at least one compound of formula (I), its salts or solvates, stereoisomers or tautomers thereof, as defined above or a pharmaceutical composition thereof.
The term “treatment” or “to treat” in the context of this specification means administration of a compound or formulation according to the invention to prevent, ameliorate or eliminate the disease or one or more symptoms associated with said disease. “Treatment” also encompasses preventing, ameliorating or eliminating the physiological sequelae of the disease.
The term “ameliorate” in the context of this invention is understood as meaning any improvement on the situation of the patient treated—either subjectively (feeling of or on the patient) or objectively (measured parameters).

Compounds of Formula I

An embodiment of the invention is directed to a compound of formula (I) wherein

- R¹is selected from —S—R³, —O—R⁴and halogen;
- R⁷is selected from —CH═N—OR⁸or —CHO;
- R³and R⁴are independently a C₁-C₆alkyl, optionally substituted by C₁-C₆alkoxy and/or —NR⁵R⁶,
- R⁵and R⁶being independently selected from hydrogen and C₁-C₆alkyl,
- R⁸is selected from hydrogen and C₁-C₆alkyl;
- or any salt or solvate or stereoisomer thereof,
- with the proviso that when R¹is Cl or OCH₃, then R⁷is not —CHO or —CH═N—OH.

Preferred compounds are those wherein R⁷is —CH═N—OR⁸, wherein R⁸is selected from hydrogen and C₁-C₆alkyl. More preferably R⁸is hydrogen.
Other preferred compounds are those wherein R¹is —S—R³, wherein R³is C₁-C₆alkyl, optionally substituted by C₁-C₆alkyl and/or NR⁵R⁶, being R⁵and R⁶independently selected from hydrogen and C₁-C₆alkyl. Even more preferred compounds are those wherein R³is selected from methyl, ethyl, propyl and isopropyl.
In another preferred embodiment, R¹is —O—R⁴, wherein R⁴is C₁-C₆alkyl, optionally substituted by C₁-C₆alkyl and/or NR⁵R⁶, being R⁵and R⁶independently selected from hydrogen and C₁-C₆alkyl. Preferably, R⁴is selected from methyl and ethyl. Even more preferably, R⁴is ethyl substituted by —NR⁵R⁶or methoxy, being R⁵and R⁶independently selected from hydrogen and C₁-C₆alkyl. Within this preferred embodiment the amine —NR⁵R⁶is primary or tertiary, being more preferably diethylamine.
In a further preferred embodiment, the double bond of the oxime group —CH═NOR⁸presents E-conformation as shown below:
According to a further embodiment, R¹is chloro.
According to a further embodiment, R¹is —S-heteroaryl, wherein the heteroaryl group is optionally substituted by C₁-C₆alkyl, preferably C₁-C₃alkyl, C₆-C₁₅aryl, halogen, —(C═O)NR⁵R⁶, —(C═O)OR⁵, C₁-C₆alkoxy and/or —NR⁵R⁶.
According to a further embodiment, R³is a C₁-C₃alkyl group substituted by —(C═O)NR⁵R⁶or —(C═O)OR⁵.
According to a preferred embodiment, the compound of formula (I) is selected from the following compounds:

4-Methoxy-[1,10]phenanthroline-2-carbaldehyde oxime
4-Methylsulfanyl-[1,10]phenanthroline-2-carbaldehyde oxime
4-Propylsulfanyl-[1,10]phenanthroline-2-carbaldehyde oxime
4-Ethoxy-[1,10]phenanthroline-2-carbaldehyde oxime
4-Isopropylsulfanyl-[1,10]phenanthroline-2-carbaldehyde oxime
4-(2-Methoxy-ethoxy)-[1,10]phenanthroline-2-carbaldehyde oxime
4-(2-Amino-ethoxy)-[1,10]phenanthroline-2-carbaldehyde oxime
4-(2-Diethylamino-ethoxy)-[1,10]phenanthroline-2-carbaldehyde oxime
4-(2-Methoxy-ethylsulfanyl)-[1,10]phenanthroline-2-carbaldehyde oxime
2-[2-(Hydroxyimino-methyl)-[1,10]phenanthrolin-4-ylsulfanyl]-N,N-dimethyl-acetamide
4-(2,2,2-Trifluoro-ethylsulfanyl)-[1,10]phenanthroline-2-carbaldehyde oxime
[2-(Hydroxyimino-methyl)-[1,10]phenanthrolin-4-ylsulfanyl]-acetic acid methyl ester
4-(Thiazol-2-ylsulfanyl)-[1,10]phenanthroline-2-carbaldehyde oxime
[2-(Hydroxyimino-methyl)-[1,10]phenanthrolin-4-ylsulfanyl]-acetic acid
4-(5-Methyl-thiazol-2-ylsulfanyl)-[1,10]phenanthroline-2-carbaldehyde oxime
4-(5-Methyl-[1,3,4]thiadiazol-2-ylsulfanyl)-[1,10]phenanthroline-2-carbaldehyde oxime
4-[1,3,4]Thiadiazol-2-ylsulfanyl)-[1,10]phenanthroline-2-carbaldehyde oxime
4-Methylsulfanyl-[1,10]phenanthroline-2-carbaldehyde
4-Propylsulfanyl-[1,10]phenanthroline-2-carbaldehyde
4-Propylsulfanyl-[1,10]phenanthroline-2-carbaldehyde oxime
4-Ethoxy-[1,10]phenanthroline-2-carbaldehyde
4-Isopropylsulfanyl-[1,10]phenanthroline-2-carbaldehyde
4-(2-Methoxy-ethoxy)-[1,10]phenanthroline-2-carbaldehyde
4-(2-Diethylamino-ethoxy)-[1,10]phenanthroline-2-carbaldehyde and salts or solvates or stereoisomers or tautomers thereof.

The compounds of formula (I) may be in the form of salts, preferably pharmaceutically acceptable salts, or in the form of solvates. The term “pharmaceutically acceptable salts” refers to any salt which upon administration to the recipient is capable of providing (directly or indirectly) a compound as described herein. However, it will be appreciated that non-pharmaceutically acceptable salts also fall within the scope of the invention since those may be useful in the preparation of pharmaceutically acceptable salts. Preferably, “pharmaceutically acceptable” refers to molecular entities and compositions that are physiologically tolerable and do not typically produce an allergic or similar untoward reaction, such as gastric upset, dizziness and the like, when administered to a human. Preferably, as used herein, the term “pharmaceutically acceptable” means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
The term “solvate” according to this invention is to be understood as meaning any form of the active compound according to the invention which has another molecule (most likely a polar solvent) attached to it via non-covalent bonding. Examples of solvates include hydrates and alcoholates, e.g. methanolate. Preferably, the solvates are pharmaceutically acceptable solvates.
The preparation of salts and solvates can be carried out by methods known in the art. For instance, pharmaceutically acceptable salts of compounds provided herein are synthesized from the parent compound, which contains a basic moiety, by conventional chemical methods. Generally, such salts are, for example, prepared by reacting the free base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent or in a mixture of the two. Generally, non-aqueous media like ether, ethyl acetate, ethanol, isopropanol or acetonitrile are preferred. Examples of the acid addition salts include mineral acid addition salts such as, for example, hydrochloride, hydrobromide, hydroiodide, sulphate, nitrate, phosphate, and organic acid addition salts such as, for example, acetate, maleate, fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate, methanesulphonate and p-toluenesulphonate.
One preferred pharmaceutically acceptable form is the crystalline form, including such form in a pharmaceutical composition. In the case of salts and solvates the additional ionic and solvent moieties must also be non-toxic. The compounds of the invention may present different polymorphic forms, it is intended that the invention encompasses all such forms.
The compounds of the invention are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by a ¹³C- or ¹⁴C-enriched carbon or a nitrogen by ¹⁵N-enriched nitrogen are within the scope of this invention.
The compounds of the present invention represented by the above described formula (I) may include enantiomers depending on the presence of chiral centres or isomers depending on the presence of multiple bonds (e.g. Z, E). The single isomers, enantiomers or diastereoisomers and mixtures thereof fall within the scope of the present invention.

Pharmaceutical Compositions

According to a further aspect, the present invention is directed to a pharmaceutical composition comprising at least one compound of formula (I) as defined above, its salts or solvates or stereoisomers or tautomers thereof, and at least one pharmaceutically acceptable carrier.
The term “carrier” refers to a diluent, adjuvant, excipient, or vehicle with which the active ingredient is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water or aqueous solution saline solutions and aqueous dextrose and glycerol solutions are preferably employed as carriers, particularly for injectable solutions. Suitable pharmaceutical carriers are described in “Remington's Pharmaceutical Sciences” by E. W. Martin, 1995.
Preferably, the carriers of the invention are approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans
The carriers and auxiliary substances necessary to manufacture the desired pharmaceutical form of administration of the pharmaceutical composition of the invention will depend, among other factors, on the elected administration pharmaceutical form. Said pharmaceutical forms of administration of the pharmaceutical composition will be manufactured according to conventional methods known by the skilled person in the art. A review of different active ingredient administration methods, excipients to be used and processes for producing them can be found in “Tratado de Farmacia Galénica”, C. Faulí i Trillo, Luzán 5, S.A. de Ediciones, 1993.
Examples of pharmaceutical compositions include any solid (tablets, pills, capsules, granules etc.) or liquid (solutions, suspensions or emulsions) compositions for oral, topical or parenteral administration.
In a preferred embodiment the pharmaceutical compositions are in oral form. Suitable dose forms for oral administration may be tablets and capsules and may contain conventional excipients known in the art such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate; disintegrants, for example starch, polyvinylpyrrolidone, sodium starch glycolate or microcrystalline cellulose; or pharmaceutically acceptable wetting agents such as sodium lauryl sulfate.
The solid oral compositions may be prepared by conventional methods of blending, filling or tabletting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are conventional in the art. The tablets may for example be prepared by wet or dry granulation and optionally coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating.
The pharmaceutical compositions may also be adapted for parenteral administration, such as sterile solutions, suspensions or lyophilized products in the appropriate unit dosage form. Adequate excipients can be used, such as bulking agents, buffering agents or surfactants.
The mentioned formulations will be prepared using standard methods such as those described or referred to in the Spanish and US Pharmacopoeias and similar reference texts.
The compounds or compositions of the present invention may be administered by any suitable method, such as intravenous infusion, oral preparations, and intraperitoneal and intravenous administration. Oral administration is preferred because of the convenience for the patient and the chronic character of many of the diseases to be treated.
Generally an effective administered amount of a compound of the invention will depend on the relative efficacy of the compound chosen, the severity of the disorder being treated and the weight of the sufferer. However, active compounds will typically be administered once or more times a day for example 1, 2, 3 or 4 times daily, with typical total daily doses in the range of from 0.01 to 1000 mg/kg/day.
According to a further aspect, the present invention is directed to a compound of formula (I), its salts or solvates or stereoisomers or tautomers thereof, as defined above, for use as a medicament.

Process for the Synthesis of a Compound of Formula I

The compounds of the present invention may be prepared by a combination of reactions known in the art.
In a particular embodiment, the compounds of formula (I) can be prepared by a process comprising:

a) oxidizing the methyl group of the compound of formula (II) with an oxidizing agent to form a compound of formula (I):

- wherein R¹is selected from —SR³, —OR⁴and halogen, being R³and R⁴independently selected from the group consisting of C₁-C₆alkyl, C₆-C₁₅aryl and heteroaryl, optionally substituted by C₁-C₆alkyl, C₆-C₁₅aryl, halogen, —(C═O)NR⁵R⁶, —(C═O)OR⁵, C₁-C₆alkoxy and/or —NR⁵R⁶; and wherein R⁵and R⁶are independently selected form hydrogen and C₁-C₆-alkyl,
- and optionally,
b) converting the aldehyde group —CHO in the compound of formula (I) into an oxime group —CH═N—OR⁸, being R⁸selected from hydrogen and C₁-C₆alkyl, in the presence of hydroxylamine or O—(C₁-C₆)alkylhydroxylamine:

According to a preferred embodiment the oxidation in step a) is carried out in the presence of oxidising agents well known to the person skilled in the art. The election of the most suitable reagent is a matter of routine experimentation for said person skilled. However, according to a preferred embodiment, the oxidation reaction is carried out in the presence of SeO₂. The solvent used in said step a) can be, but is not limited to, dioxane.
According to another preferred embodiment the step b) can be carried out in a mixture of an alcohol, such as ethanol, and an aqueous sodium salt, such as sodium hydroxide.
In a further aspect, the present invention refers to a process for the preparation of a compound of formula (I) which comprises:

- a) reacting the compound formula (III) with a sodium salt of the corresponding alcoxide or thiolate of formula —OR³or —OR⁴, to form a compound of formula (II):

- - wherein
  - X is an halogen;
- R¹is selected from —S—R³, —O—R⁴and halogen;
  - R³and R⁴are independently selected from the group consisting of C₁-C₆alkyl, C₆-C₁₅aryl and heteroaryl, optionally substituted by C₁-C₆alkyl, C₆-C₁₅aryl, halogen, —(C═O)NR⁵R⁶, —(C═O)OR⁵, C₁-C₆alkoxy and/or —NR⁵R⁶;
  - provided that when R¹in the formula (II) is an halogen this step is omitted;
- b) oxidising the methyl group of the compound of formula (II) with an oxidizing agent to form a compound of formula (I);

- - wherein R¹is as defined in step a);
- and, optionally
- c) converting the aldehyde group —CHO in the compound of formula (I) into an oxime group —CH═N—OR⁸, being R⁸selected from hydrogen and C₁-C₆alkyl, in the presence of hydroxylamine or O—(C₁-C₆)alkylhydroxylamine:

- - wherein R¹is as defined in step a).

The corresponding alkoxide or thiolate as defined is step a) results from the reaction of the corresponding alcohol or thiol with a suitable inorganic sodium salt. In a preferred embodiment, the sodium salt is sodium ethoxide, sodium 2-propanethiolate or sodium 1-propanethiolate.
In another preferred embodiment of this process, step a) is carried out in an alcohol or tetrahydrofurane as solvent.
The starting compound of formula (III) can be prepared by methods known by a skilled person. For example, it may be synthesized by first reacting the compound quinolin-8-ylamine with ethyl acetoacetate in the presence of hydrochloride acid as catalyst to form 2-methyl-[1,10]phenanthrolin-4-ol, according to the process described in Proc. R. Soc. N.S.W. 1938, 71, 462-474. Subsequently, the phenanthroline obtained in the first reaction is subjected to an halogenation reaction, such as for example in the presence of POCl₃, to form the compound of formula (III), according to the process described in J. Med. Chem., 2003, 46, 4463-4476.
In the following, the present invention is further illustrated by examples. They should in no case be interpreted as a limitation of the scope of the invention as defined in the claims.

EXAMPLES

In the present examples, the following compounds of formula (I) are being referred to:

Synthesis of the Compounds

Compounds of formula (I) according to the present invention were prepared following the general preparation strategy detailed below.
In the following, the particular syntheses of compounds 4 to 10, with structures as detailed in table 1, are described.
The compounds 4 to 10 were synthesized starting from a common intermediate for which the method of preparation is described below.

Synthesis of the intermediate 4-chloro-2-methyl-[1,10]phenanthroline

1. Preparation of 2-Methyl-[1,10]phenathrolin-4-ol

Synthetic procedure was adapted from Hazlewood, S. J.; Hughes, G. K.; Lions F., J. Proc. R. Soc. N. S. W. 1938, 71, 462-474.
In a 100 mL round-bottomed flask 8-aminoquinoline (15.00 g, 104.0 mmol) and ethyl acetoacetate (13.50 g, 104.0 mmol) were stirred at 100° C. for 24 hours in the presence of a catalytic amount of 1N HCl (10 drops). The reaction mixture was allowed to reach room temperature and toluene (20 mL) was added, which was later removed in a rotary evaporator. The same process of dilution with toluene and solvent removal was repeated at least three times. The dark oily crude enamine obtained was dissolved in diphenyl ether (20 mL) and was transferred to an addition funnel connected to a 250 mL round-bottomed flask containing diphenyl ether (100 mL). The flask was heated to reflux and the enamine solution was slowly added over a period of 15 minutes, and reflux was maintained for additional 20 minutes. The reaction mixture was cooled down to room temperature and the crystalline material formed was filtered, washed with ethyl ether and dried. A light brown solid (10.20 g, 47% yield) was obtained.

2. Preparation of 4-Chloro-2-methyl-[1,10]phenanthroline

Synthetic procedure was adapted from Harrison R. J.; Cuesta J.; Chessari, G.; Read M. A.; Basra, S. K.; Reszka, A. P.; Morrell, J.; Gowan, S. M.; Incles, C. M.; Tanious, F. A.; Wilson, W. D.; Kelland, L. R.; Neidle, S., J. Med. Chem. 2003, 46, 4463-4476.
To a 500 mL round-bottomed flask equipped with a reflux condenser containing 2-methyl-[1,10]phenathrolin-4-ol, (10.20 g, 48.5 mmol), was slowly added phosphorus oxychloride (200 mL) and the mixture was refluxed for 3 hours. The reaction flask was allowed to cool down to room temperature and the solvent was removed in a rotary evaporator. The solid obtained was treated with methylene chloride (200 mL) and saturated NaHCO₃(200 mL) and transferred to a separatory funnel. The aqueous layer was further extracted with methylene chloride (200 mL) and the combined organic layers were washed with brine (200 mL), dried (Na₂SO₄), filtered and concentrated. The residue obtained was treated with ethyl ether (100 mL), filtered and dried yielding a light brown solid (9.00 g). A second crop of 0.60 g of material was obtained from the mother liquors as a light yellow solid, with an overall yield of 9.60 g (87% yield).

Example 1

Preparation of 4-Methylsulfanyl-[1,10]phenanthroline-2-carbaldehyde oxime (Compound 4)

1. Synthesis of 2-Methyl-4-methylsulfanyl-[1,10]phenanthroline

Solid sodium methanethiolate (3.30 g, 47.7 mmol) was added to a 100 mL round-bottomed flask containing a solution of 4-chloro-2-methyl-[1,10]phenanthroline (intermediate obtained previously), (2.10 g, 9.4 mmol) in methanol (50 mL). The reaction mixture was refluxed for 18 hours and allowed to cool down to room temperature afterwards. The solvent was removed in a rotary evaporator and the residue was treated with methylene chloride (100 mL) and saturated NaHCO₃(100 mL) and transferred to a separatory funnel. The organic layer was washed with brine (100 mL), dried (Na₂SO₄), filtered and concentrated in vacuo. The solid residue was treated with ethyl ether, filtered and dried, yielding 1.90 g of a light brown solid (84%).

2. Synthesis of 4-Methylsulfanyl-[1,10]phenanthroline-2-carbaldehyde

A solution of SeO₂(2.18 g, 19.6 mmol) in a mixture of dioxane (100 mL) and water (4 mL) was heated to reflux in a two-neck 250 mL round-bottomed flask. A solution of 2-methyl-4-methylsulfanyl-[1,10]phenanthroline (1.89 g, 7.90 mmol) in hot dioxane (100 mL) was added through an addition funnel over a period of 1 hour and the reaction mixture was refluxed for additional 45 minutes. The reaction mixture was filtered while hot and the residue rinsed with more hot dioxane (20 mL) and filtered. The filtrate was concentrated in vacuo and the residue obtained was redissolved in hot water, stirred with decolorizing charcoal and filtered. The filtrate was allowed to reach room temperature and basified with saturated NaHCO₃until precipitation of a white solid, which was filtered, washed with cold water and dried in vacuo. A white solid (0.80 g, 41% yield) was obtained.

3. Synthesis of 4-Methylsulfanyl-[1,10]phenanthroline-2-carbaldehyde oxime

To a 25 mL round-bottomed flask containing a solution of 4-methylsulfanyl-[1,10]phenanthroline-2-carbaldehyde (228.0 mg, 1.1 mmol) in ethanol (3.2 mL), a solution of hydroxylamine hydrochloride (707.0 mg, 10.2 mmol) in water (5.0 mL) was added followed by the addition of 10% NaOH until a precipitate was formed. The reaction mixture was heated to 90° for about 30 minutes, cooled to room temperature and the white precipitate was filtered, washed with cold water and dried. White solid (240.0 mg, 100%) was obtained.
¹H NMR (DMSO-d₆, 400 MHz):
11.95 (s, 1H); 9.12 (dd, 1H, J=1.6, 4.2 Hz); 8.50 (dd, 1H, J=1.6, 8.1 Hz); 8.33 (s, 1H); 8.06 (AB system, 2H, S_AB=9.1 Hz); 7.92 (s, 1H); 7.78 (dd, 1H, J=4.2, 8.1 Hz); 2.72 (s, 3H)
¹³C NMR (DMSO-d₆, 100 MHz):
151.2; 150.3; 149.1; 148.5; 145.1; 144.2; 136.2; 128.4; 127.1; 125.3; 123.5; 121.1, 121.0; 112.5; 13.4

Example 2

Synthesis of 4-Propylsulfanyl-[1,10]-phenanthroline-2-carbaldehyde oxime (Compound 5)

1. Synthesis of 2-Methyl-4-propylsulfanyl-[1,10]phenanthroline

Solid sodium 1-propanethiolate (2.35 g, 24.0 mmol) was added to a 100 mL round-bottomed flask containing a solution of 4-chloro-2-methyl-[1,10]phenanthroline (1.10 g, 4.8 mmol) in methanol (50 mL). The reaction mixture was refluxed for 18 hours and allowed to reach room temperature. The solvent was removed in a rotary evaporator and the residue was treated with methylene chloride (100 mL) and saturated NaHCO₃(100 mL) and transferred to a reparatory funnel. The organic layer was washed with brine (100 mL), dried (Na₂SO₄), filtered and concentrated in vacuo. The solid residue was treated with ethyl ether, filtered, and dried yielding 0.98 g of a dark orange solid (76%).

2. Synthesis of 4-Propylsulfanyl-[1,10]phenanthroline-2-carbaldehyde

A solution of SeO₂(0.98 g, 8.8 mmol) in a mixture of dioxane (50 mL) and water (2 mL) was heated to reflux in a two-neck 250 mL round-bottomed flask. A solution of 2-methyl-4-propylsulfanyl-[1,10]phenanthroline (0.95 g, 3.5 mmol) in hot dioxane (50 mL) was added through an addition funnel over a period of 30 minutes and the reaction mixture was refluxed for additional 1 hour. The reaction mixture was filtered while hot and the residue rinsed with more hot dioxane (20 mL) and filtered. The filtrates were combined and evaporated in vacuo and the residue was treated with methylene chloride (100 mL) and a 10% K₂CO₃aqueous solution (100 mL). The aqueous layer was extracted several times with methylene chloride (3×100 mL) and the combined organic layers were washed with brine, dried (Na₂SO₄), filtered and concentrated. The crude product was purified by flash chromatography (neutral Al₂O₃, MeOH/DCM, 1:50 to 1:15) to afford the pure product as a brown solid (0.27 g, 27%).

3. Synthesis of 4-Propylsulfanyl-[1,10]phenanthroline-2-carbaldehyde oxime

The final step to obtain the Compound 5 is carried out in the same way as described in the synthesis of Compound 4.
¹H NMR (DMSO-d₆, 400 MHz):
11.96 (s, 1H); 9.11 (dd, 1H, J=1.6, 4.0 Hz); 8.49 (dd, 1H, J=1.6, 8.0 Hz); 8.33 (s, 1H); 8.10 (d, 1H, J=9.2 Hz); 8.03 (d, 1H, J=9.2 Hz); 7.96 (s, 1H); 7.78 (dd, 1H, J=4.0, 8.0 Hz); 3.23 (t, 2H, J=7.2 Hz); 1.79 (m, 2H); 1.08 (t, 3H, J=7.2 Hz)
¹³C NMR (DMSO-d₆, 100 MHz):
151.09; 150.29; 149.14; 147.45; 145.17; 144.54; 136.20; 128.42; 127.09; 125.59; 123.50; 121.25; 113.31; 32.19; 21.00; 13.28

Example 3

Preparation of 4-Ethoxy-[1,10]-phenanthroline-2-carbaldehyde oxime (Compound 6)

1. Synthesis of 2-Methyl-4-ethoxy-[1,10]phenanthroline

Solid sodium ethoxide (2.97 g, 48.0 mmol) was added to a 100 mL round-bottomed flask containing a solution of 4-chloro-2-methyl-[1,10]-phenanthroline (1.10 g, 4.8 mmol) in ethanol (50 mL). The reaction mixture was refluxed for 18 hours. The solvent was removed in a rotary evaporator and the residue was treated with methylene chloride (100 mL) and saturated NaHCO₃(100 mL) and transferred to a separatory funnel. The organic layer was washed with brine (100 mL), dried (Na₂SO₄), filtered and concentrated in vacuo. The solid residue was treated with ethyl ether, filtered, and dried yielding 0.89 g of a brown solid (78%).

2. Synthesis of 4-Ethoxy-[1,10]phenanthroline-2-carbaldehyde

A solution of SeO₂(1.01 g, 9.1 mmol) in a mixture of dioxane (50 mL) and water (2 mL) was heated to reflux in a two-neck 250 mL round-bottomed flask. A solution of 2-methyl-4-ethoxy-[1,10]phenanthroline (0.87 g, 3.6 mmol) in hot dioxane (50 mL) was added through an addition funnel over a period of 30 minutes and the reaction mixture was refluxed for 1 hour. The reaction mixture was filtered while hot and the residue rinsed with more hot dioxane (20 mL) and filtered. The filtrates were combined and concentrated in vacuo and the residue was treated with methylene chloride (100 mL) and a 10% K₂CO₃aqueous solution (100 mL). The aqueous layer was extracted with methylene chloride (3×100 mL) and the combined organic layers were washed with brine, dried (Na₂SO₄), filtered and concentrated. The crude product was purified by flash chromatography (SiO₂, MeOH/DCM, 1:30 to 1:15) to afford the pure product as a light brown solid (0.15 g, 16%).

3. Synthesis of 4-Ethoxy-[1,10]phenanthroline-2-carbaldehyde oxime

The final step to obtain the Compound 6 is carried out in the same way as described in the synthesis of Compound 4.
¹H NMR (DMSO-d₆, 400 MHz):
11.85 (s, 1H); 9.10 (dd, 1H, J=1.6, 4.0 Hz); 8.48 (dd, 1H, J=1.6, 8.0 Hz); 8.32 (s, 1H); 8.17 (d, 1H, J=9.2 Hz); 7.96 (d, 1H, J=9.2 Hz); 7.76 (dd, 1H, J=4.0, 8.0 Hz); 7.57 (s, 1H); 4.39 (q, 2H, J=6.8 Hz); 1.52 (t, 3H, J=6.8 Hz)
¹³C NMR (DMSO-d₆, 100 MHz):
160.85; 153.28; 149.96; 149.61; 146.06; 144.96; 136.15; 128.61; 126.05; 123.27; 120.27; 119.57; 99.11; 64.34; 14.22

Example 4

Preparation of 4-Isopropylsulfanyl-[1,10]-phenanthroline-2-carbaldehyde oxime (Compound 7)

1. Synthesis of 2-Methyl-4-isopropylsulfanyl-[1,10]phenanthroline

Solid sodium 2-propanethiolate (2.35 g, 24.0 mmol) was added to a 100 mL round-bottomed flask containing a solution of 4-chloro-2-methyl-[1,10]phenanthroline (1.10 g, 4.8 mmol) in methanol (50 mL). The reaction mixture was refluxed for 18 hours. The solvent was removed in a rotary evaporator and the residue was treated with methylene chloride (100 mL) and saturated NaHCO₃(100 mL) and transferred to a separatory funnel. The organic layer was washed with brine (100 mL), dried (Na₂SO₄), filtered and concentrated in vacuo. The residue was purified by flash chromatography (SiO₂, MeOH/DCM, 1:80) to afford the pure product as a yellow oil (1.03 g, 80%).

2. Synthesis of 4-Isopropylsulfanyl-[1,10]phenanthroline-2-carbaldehyde

A solution of SeO₂(1.06 g, 9.6 mmol) in a mixture of dioxane (50 mL) and water (2 mL) was heated to reflux in a two-neck 250 mL round-bottomed flask. A solution of 2-methyl-4-isopropylsulfanyl-[1,10]phenanthroline (1.03 g, 3.8 mmol) in hot dioxane (50 mL) was added through an addition funnel over a period of 30 minutes and the reaction mixture was refluxed for 1 hour. The reaction mixture was filtered while hot and the residue rinsed with more hot dioxane (20 mL) and filtered. The filtrates were combined and concentrated in vacuo and the residue was treated with methylene chloride (100 mL) and a 10% K₂CO₃aqueous solution (100 mL). The aqueous layer was extracted several times with methylene chloride (3×100 mL) and the combined organic layers were washed with brine, dried (Na₂SO₄), filtered and concentrated. The crude product was purified by flash chromatography (neutral Al₂O₃, MeOH/DCM, 1:50 to 1:15) to afford the pure product as a light yellow solid (0.44 g, 41%).

3. Synthesis of 4-Isopropylsulfanyl-[1,10]phenanthroline-2-carbaldehyde oxime

The final step to obtain the Compound 7 is carried out in the same way as described in the synthesis of Compound 4.
¹H NMR (DMSO-d₆, 400 MHz):
11.98 (s, 1H); 9.12 (dd, 1H, J=1.6, 4.0 Hz); 8.51 (dd, 1H, J=1.6, 8.0 Hz); 8.35 (s, 1H); 8.12 (d, 1H, J=9.2 Hz); 8.04 (d, 1H, J=9.2 Hz); 8.03 (s, 1H); 7.79 (dd, 1H, J=4.0, 8.0 Hz, 1H); 3.89 (m, 1H); 1.46 (d, 6H, J=6.4 Hz)
¹³C NMR (DMSO-d₆, 100 MHz):
151.12; 150.28; 149.13; 146.52; 145.18; 144.81; 136.19; 128.43; 127.11; 125.97; 123.52; 121.44; 114.84; 35.40; 22.27

Example 5

Preparation of 4-(2-Methoxy-ethoxy)-[1,10]-phenanthroline-2-carbaldehyde oxime (Compound 8)

1. Synthesis of 4-(2-Methoxy-ethoxy)-2-methyl-[1,10]phenanthroline

To a suspension of sodium hydride (60% in mineral oil, 1.75 g, 43.7 mmol) in THF (30 mL) a solution of 2-methoxyethanol (3.30 g, 43.7 mmol) in anhydrous THF (10 mL) was slowly added. The mixture was stirred at room temperature for 20 minutes and a solution of 4-chloro-2-methyl-[1,10]phenanthroline (2.00 g, 8.8 mmol) in anhydrous THF (20 mL) was added. The reaction mixture was refluxed for 18 hours and the solvent was removed in a rotary evaporator. The residue was treated with methylene chloride (100 mL) and saturated NaHCO₃(100 mL) and transferred to a separatory funnel. The organic layer was washed with brine (100 mL), dried (Na₂SO₄), filtered and concentrated in vacuo. The residue was washed with hexane and purified by flash chromatography (SiO₂, MeOH/DCM, 1:30) to afford the pure product as a light yellow solid (1.17 g, 50%).

2. Synthesis of 4-(2-Methoxy-ethoxy)-[1,10]phenanthroline-2-carbaldehyde

A solution of SeO₂(1.19 g, 10.8 mmol) in a mixture of dioxane (50 mL) and water (2 mL) was heated to reflux in a two-neck 250 mL round-bottomed flask. A solution of 4-(2-methoxy-ethoxy)-2-methyl-[1,10]phenanthroline (1.16 g, 4.3 mmol) in hot dioxane (30 mL) was added through an addition funnel over a period of 10 minutes and the reaction mixture was refluxed for 30 minutes. The solvent was evaporated in vacuo and the residue was treated with methylene chloride (200 mL) and saturated NaHCO₃(200 mL). The aqueous layer was extracted several times with methylene chloride (3×100 mL) and the combined organic layers were washed with brine, dried (Na₂SO₄), filtered and evaporated. The crude product was purified by flash chromatography (SiO₂, MeOH/DCM, 1:40 to 1:20) to afford the pure product as a pale solid (0.65 g, 53%).

3. Synthesis of 4-(2-Methoxy-ethoxy)-[1,10]phenanthroline-2-carbaldehyde oxime

The final step to obtain the Compound 8 is carried out in the same way as described in the synthesis of Compound 4.
¹H NMR (DMSO-d₆, 400 MHz):
11.94 (s, 1H); 9.06 (dd, 1H, J=1.6, 4.0 Hz); 8.46 (dd, 1H, J=1.2, 8.0 Hz); 8.35 (s, 1H); 8.13 (d, 1H, J=8.8 Hz); 7.95 (d, 1H, J=8.8 Hz); 7.75 (dd, 1H, J=4.4, 8.0 Hz); 7.57 (s, 1H); 4.43 (t, 2H, J=4.4 Hz); 3.83 (t, 2H, J=4.4 Hz); 3.36 (s, 3H)
¹³C NMR (DMSO-d₆, 100 MHz):
161.3; 153.5; 150.3; 150.0; 146.1; 145.0; 136.6; 128.9; 126.4; 123.7; 120.5; 119.9; 99.7; 70.2; 68.4; 58.6

Example 6

Preparation of 4-(2-Amino-ethoxy)-[1,10]-phenanthroline-2-carbaldehyde oxime (Compound 9)

1. Synthesis of [2-(2-Methyl-[1,10]phenanthrolin-4-yloxy)-ethyl]-carbamic acid tert-butyl ester

To a suspension of sodium hydride (60% in mineral oil, 0.87 g, 21.8 mmol) in THF (15 mL) a solution of N-Boc-2-hydroxyethylamine (1.75 g, 21.8 mmol) in anhydrous THF (5 mL) was slowly added. The mixture was stirred at room temperature for 20 minutes and a solution of 4-chloro-2-methyl-[1,10]phenanthroline (1.00 g, 4.4 mmol) in anhydrous THF (20 mL) was slowly added. The reaction mixture was refluxed for 18 hours and the solvent was removed in a rotary evaporator. The residue was treated with methylene chloride (100 mL) and saturated NaHCO₃(100 mL) and transferred to a separatory funnel. The organic layer was washed with brine (100 mL), dried (Na₂SO₄), filtered and concentrated in vacuo. The residue was washed with hexane and purified by flash chromatography (SiO₂, MeOH/DCM, 1:40) to afford the pure product as a pale solid (0.72 g, 46%).

2. Synthesis of [2-(2-Formyl-[1,10]phenanthrolin-4-yloxy)-ethyl]carbamic acid tert-butyl ester

A solution of SeO₂(0.56 g, 5.1 mmol) in a mixture of dioxane (25 mL) and water (2 mL) was heated to reflux in a two-neck 100 mL round-bottomed flask. A solution of [2-(2-methyl-[1,10]phenanthrolin-4-yloxy)-ethyl]-carbamic acid tert-butyl ester (0.72 g, 2.0 mmol) in hot dioxane (20 mL) was added through an addition funnel over a period of 15 minutes and the reaction mixture was refluxed for 45 minutes. The solvent was evaporated in vacuo and the residue was treated with methylene chloride (100 mL) and saturated NaHCO₃(100 mL). The aqueous layer was extracted with methylene chloride (3×100 mL) and the combined organic layers were washed with brine, dried (Na₂SO₄), filtered and concentrated. The crude product was obtained as a yellow solid (0.52 g, 69%) and was pure enough to be used in further synthetic steps without additional purification.

3. Synthesis of 4-(2-Amino-ethoxy)-[1,10]phenanthroline-2-carbaldehyde oxime

A solution of [2-(2-formyl-[1,10]phenanthrolin-4-yloxy)-ethyl]carbamic acid tert-butyl ester (0.52 g, 1.4 mmol) was stirred for 1 hour at room temperature in a mixture of trifluoroacetic acid (5 mL) and methylene chloride (10 mL). The solvent was removed and the residue was dried and redissolved in ethanol (5 mL). A solution of hydroxylamine hydrochloride (0.88 g, 12.7 mmol) in water (7 mL) was added followed by the addition of 10% NaOH until a white precipitate formed. The mixture was heated to reflux for 1 hour, cooled down to room temperature and the white precipitate filtered, washed with cold water and dried. The title compound was isolated as a pale solid (37.0 mg, 9%)
¹H NMR (DMSO-d₆, 400 MHz):
12.13 (s, 1H); 9.09 (dd, 1H, J=1.2 Hz, J=4.0 Hz); 8.50 (dd, 1H, J=1.2 Hz, J=8.0 Hz); 8.40 (m, 2H); 7.97 (d, 1H, J=8.8 Hz); 7.81 (dd, 1H, J=4.0 Hz, J=8.0 Hz); 7.26 (s, 1H); 3.73 (d, 2H, J=9.2 Hz); 3.52 (d, 2H, J=9.2 Hz)
¹³C NMR (DMSO-d₆, 100 MHz):
152.72, 150.00, 146.82, 136.29, 128.51, 124.69, 124.00, 120.02, 116.91, 104.21, 96.79, 58.68, 45.62

Example 7

Preparation of 4-(2-Diethylamino-ethoxy)-[1,10]-phenanthroline-2-carbaldehyde oxime (Compound 10)

1. Synthesis of diethyl-[2-(2-methyl-[1,10]phenanthrolin-4-yloxy)-ethyl]amine

To a suspension of sodium hydride (60% in mineral oil, 5.25 g, 131.1 mmol) in anhydrous THF (90 mL) a solution of N,N-diethyl-2-hydroxyethylamine (15.30 g, 131.1 mmol) in anhydrous THF (60 mL) was slowly added. The mixture was stirred at room temperature for 20 minutes and a solution of 4-chloro-2-methyl-[1,10]phenanthroline (6.00 g, 26.2 mmol) in anhydrous THF (90 mL) was slowly added. The reaction mixture was refluxed for 18 hours and then allowed to cool down to room temperature, quenched with 1N HCl and evaporated. The residue was redissolved in 1N NaOH (150 mL) and extracted with methylene chloride (3×200 mL). The combined organic layers were dried (Na₂SO₄), filtered and concentrated in vacuo. The residue was washed with hexane and purified by flash chromatography (SiO₂, MeOH/DCM, 1:40) to yield the pure product as an orange oil (5.1 g, 63%).

2. Synthesis of 4-(2-Diethylamino-ethoxy)-[1,10]phenanthroline-2-carbaldehyde

A solution of SeO₂(0.83 g, 7.5 mmol) in a mixture of dioxane (38 mL) and water (3 mL) was heated to reflux in a two-neck 100 mL round-bottomed flask. A solution of diethyl-[2-(2-methyl-[1,10]phenanthrolin-4-yloxy)-ethyl]amine (0.93 g, 3.0 mmol) in hot dioxane (20 mL) was added through an addition funnel over a period of 15 minutes and the reaction mixture was refluxed for 45 minutes. The solvent was evaporated in vacuo and the residue was treated with methylene chloride (100 mL) and saturated NaHCO₃(100 mL). The aqueous layer was extracted with methylene chloride (3×100 mL) and the combined organic layers were washed with brine, dried (Na₂SO₄), filtered and concentrated. The crude product was purified by flash chromatography (SiO₂, MeOH/DCM, 1:40) to afford the pure material as a brown solid (0.19 g, 19%).

3. Synthesis of 4-(2-Diethylamino-ethoxy)-[1,10]phenanthroline-2-carbaldehyde oxime

The final step to obtain the Compound 10 is carried out in the same way as described in the synthesis of Compound 4.
¹H NMR (DMSO-d₆, 400 MHz):
11.85 (s, 1H); 9.09 (dd, 1H, J=2.0, 4.4 Hz); 8.46 (dd, 1H, J=1.0, 8.0 Hz); 8.31 (s, 1H); 8.13 (d, 1H, J=8.8 Hz); 7.96 (d, 1H, J=8.8 Hz); 7.92 (s, 1H); 7.75 (dd, 1H, J=4.4, 8.0 Hz); 4.36 (t, 2H, J=5.6 Hz); 2.96 (t, 2H, J=5.6 Hz); 2.60 (q, 4H, 7.2 Hz); 1.01 (t, 6H, d=7.2 Hz)
¹³C NMR (DMSO-d₆, 100 MHz):
161.0; 153.3; 150.0; 149.6; 146.1; 145.0; 136.2; 128.6; 126.1; 123.3; 120.3; 119.5; 99.3; 67.5; 50.8; 47.1; 12.0

Biology

Example 8

Toxicity

The potential effects on cell viability of the assayed compounds are assayed in SH-SY5Y human neuroblastoma cells, by quantification of Lactate dehydrogenase (LDH) activity release. SH-SY5Y human neuroblastoma cells are seeded into 96-well culture plates at 104 cells/well. The medium is then removed and the cells incubated with different concentrations of the compounds during 24 h. The compounds are tested at increasing concentrations starting from 1 μM, in fresh culture medium, in order to find the minimum concentration at which the compounds are toxic, up to a maximum of 1 mM. After 24 h, the medium is removed and cells attached to the bottom of the well are lysed by adding 50 μl of Krebs-Hepes; Triton X-100 1% during 5 minutes at room temperature. For LDH release quantification, the Roche cytotoxicity detection kit (Cat. No. 11 644 793 001) is used. The LDH activity is measured by its absorbance at 492 nm with reference wavelength 620 nm.
In Table 1, for each compound the maximum concentration at which toxicity was tested is indicated in the second column. In the third column, it is indicated whether at this maximum concentration the compound was toxic or not. All the compounds, with the exception of Compound 3, resulted non-toxic at the concentration for which activity was found, in most of the cases even at a 1000-fold concentration. Thus, the compounds may be considered non-toxic.

TABLE 1

	Maximum
	concentration tested
Compound No.	for toxicity	Yes/No

	Compound 1	1	mM	Yes
	Compound
2	1	mM	Yes
	Compound 3	10	μM	Yes
	Compound
4	1	mM	Yes
	Compound 5	1	mM	Yes
	Compound 6	1	mM	Yes
	Compound
7	1	mM	Yes
	Compound
8	1	mM	No
	Compound 9	10	μM	No
	Compound
10	1	μM	Yes
	Compound 12	1000	μM	No
	Compound 13	1000	μM	No
	Compound 14	1000	μM	Yes
	Compound 15	100	μM	Yes
	Compound 16	10	μM	Yes
	Compound 17	1000	μM	Yes
	Compound 18	10	μM	Yes
	Compound 19	10	μM	Yes
	Compound 20	10	μM	Yes

Example 9

Protection Against Hydrogen Peroxide-Induced Cell Death

The aim of this assay is to determine the neuroprotective effect of the compounds of formula (I), when human neuroblastoma cells are exposed to oxidative stress induced by hydrogen peroxide, which is highly deleterious to the cell and its accumulation causes oxidation of cellular targets such as DNA, proteins, and lipids leading to mutagenesis and cell death.
SH-SY5Y human neuroblastoma cells are seeded into 96-well culture plate at a density of 104 cells/well. Cells are exposed to different concentrations of the compound one hour before the treatment with H₂O₂100 μM during 24 h. 5 mM N-acetylcysteine (NAC), a known anti-oxidant agent was used as a positive control, and preincubated 1 hour before the treatment with H₂O₂. After 24 h, the medium is removed and cells attached to the bottom of the well are lysed by adding 50 μl of Triton X-100 1% in Krebs-Hepes during 5 minutes at room temperature. For LDH release quantification, Roche cytotoxicity detection kit (Cat. No. 11 644 793 001) was used.
The minimum concentration of Compounds I-10 for which protection against H₂O₂was determined are shown in Table 2.

	TABLE 2

	Compound No.	Protect. H₂O₂

	Compound 1	0.05	μM
	Compound
2	0.05	μM
	Compound 3	10	μM
	Compound
4	0.05	μM
	Compound 5	5	nM
	Compound 6	5	nM
	Compound
7	0.05	μM
	Compound
8	50	nM
	Compound 9	5	μM
	Compound
10	50	nM
	Compound 12	0.1	μM
	Compound 13	0.5	μM
	Compound 14	0.05	μM
	Compound 15	0.5	μM
	Compound 16	0.05	μM
	Compound 17	5	μM
	Compound 18	0.05	μM
	Compound 19	0.5	μM
	Compound 20	0.5	μM

Protection Against 6-OHDA-Induced Cell Death

The aim of this experiment is to determine the protective effect of the compounds of formula (I) against the toxicity caused by 6-OHDA. This toxin induces a cell death similar to which occurs in Parkinson's disease, destroying dopaminergic neurons (“MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson's disease: neuroprotective strategies”; Grunblatt E, et al.; J. Neurol. 2000 April; 247 Suppl 2:1195-102).
Two or three days before the experiment, the SH-SY5Y human neuroblastoma cells are seeded into 96-well culture plate at a density of 10⁴cells/well. Cells are exposed to the treatment with 6-OHDA and, finally, cell death is measured by LDH quantification. As positive control we used NAC.
The assay is performed in two different experimental conditions:

Example 10

A) NAC and the compound of formula (I) are preincubated during 2 hours before the treatment with 6-OHDA 75 μM during 16 hours. The assay is performed in medium containing 10% Foetal bovine serum.
The neuroprotective results against cellular death induced by 6-OHDA are shown in Table 3. For each compound the minimum concentration of compound of formula (I) at which a neuroprotective effect is shown.

	TABLE 3

	Compound No.	Protect. 6-OHDA (+FBS)

	Compound 1	0.5 μM
	Compound
2	0.5 μM
	Compound
4	0.05 μM
	Compound 5	0.05 μM
	Compound 6	0.05 μM
	Compound
7	0.05 μM
	Compound
8	0.05 μM
	Compound 9	5 μM
	Compound
10	0.05 μM
	Compound 12	0.1 μM
	Compound 13	0.5 μM
	Compound 14	0.5 μM
	Compound 16	0.5 μM
	Compound 18	0.05 μM

Example 11

B) NAC and the compound of formula (I) are preincubated during 1 hour before the treatment with 6-OHDA 50 μM during 24 hours. The assay is performed in a medium without any fetal bovine serum.
The neuroprotective results against cellular death induced by 6-OHDA are shown in Table 4. For each compound the minimum concentration of compound of formula (I) at which a neuroprotective effect is shown.

	TABLE 4

	Compound No.	Protect. 6-OHDA (−FBS)

	Compound 1	0.5 μM
	Compound
2	0.5 μM
	Compound 3	10 μM
	Compound
4	0.5 μM
	Compound 5	0.5 μM
	Compound 6	0.5 μM
	Compound
7	0.5 μM
	Compound
8	0.5 μM
	Compound 9	5 μM
	Compound
10	0.5 μM
	Compound 12	0.5 μM
	Compound 13	5 μM
	Compound 14	0.5 μM
	Compound 16	10 μM
	Compound 18	10 μM

Example 12

Neuroprotection Against Aβ Toxicity

In order to evaluate potential neuroprotection of compounds, SH-SY5Y cells, cultured in 96-well plates, were pre-treated for 1 hour with the compound at different concentrations and then exposed 24 hours to 200 μM Aβ_25-35(Neosystem) to induce extensive oxidative stress and cell death. The ability of the compound of protecting against this toxicity is then evaluated by measuring intracellular LDH, using the colorimetric LDH assay.
It is widely accepted that the neurotoxic activity of Aβ resides within amino acids 25-35 (see e.g. Yankner B A et al., (1990) Neurotrophic and neurotoxic effects of amyloid β protein: reversal by tachykinin neuropeptides; Science 250:279-282).
In Table 5, the minimum concentration at which the tested compounds showed neuroprotection against Aβ_25-35toxicity is shown.

	TABLE 5

	Compound No.	Protect. beta-Amyloid_25-35

	Compound 1	5 μM
	Compound
2	10 μM
	Compound
4	0.5 μM
	Compound 6	10 μM
	Compound
8	0.5 μM
	Compound 9	5 μM
	Compound
10	0.5 μM
	Compound 12	10 μM
	Compound 13	5 μM
	Compound 14	10 μM
	Compound 16	5 μM
	Compound 18	10 μM

Example 13

Inhibition of Aβ(1-40) Secretion

To quantitate Aβ secretion ELISA-based method was used. The assay consists in detection of antigen by selective monoclonal anti-Aβ-antibodies at two different epitopes forming a “Sandwich-complex”, that is detected by colorimetric measure due to the binding of a secondary antibody conjugated with peroxidase that catalyses the conversion of a substrate or chromogen, TMB, into a coloured product, directly proportional to the peptide quantity in the sample. The Aβ production has been analyzed by ELISA, using a colorimetric commercial kit: Immunoassay Kit Human β Amyloid 1-40 (Biosource).
Aβ (1-40) were quantified from cellular supernatants. An APP-transfected cell line has been employed for the experiments: CHO7W (stably transfected with human APP₇₅₁wt cDNA). The cells were grown in a culture medium consisting of DMEM supplemented with 2% Fetal bovine serum, 1% penicillin-streptomycin, 1% L-glutamine and 200 μg/ml G418. Cells are seeded in 96-well culture microplate, at 5000 cells/well and treatment with different compounds at different concentrations is performed 24 hour after seeding.
OM99-2 (H-5108, Bachem), a BACE inhibitor, was used as Aβ secretion reduction positive control in all the Aβ secretion studies. The cells were treated with this compound at 3 μM concentration, culture media were collected at 24 hours. At this concentration OM99-2 shows a percentage of Aβ release inhibition between 20 and 60%.
In Table 6 the minimum concentration for each tested compound at which the compound inhibits beta-amyloid inhibition is shown.

	TABLE 6

		Inhibition secretion beta-
	Compound No.	amyloid

Compound

1	0.01	mM
	Compound
2	1	mM
	Compound
4	0.05	mM
	Compound 5	1	nM
	Compound 6	10	nM
	Compound
7	1	nM
	Compound
8	1	mM
	Compound 9	10	mM
	Compound
10	1	mM
	Compound 12	1	μM
	Compound 13	10	μM
	Compound 14	0.01	μM
	Compound 15	10	μM
	Compound 16	1	μM
	Compound 17	10	μM
	Compound 18	0.1	μM
	Compound 19	1	μM
	Compound 20	10	μM

Example 14

Screening Pharmacokinetic Study

The objective of this study is to evaluate the oral bioavailability and the plasmatic and brain pharmacokinetic parameters after oral and intravenous administration, thus determining if compounds of formula (I) are able to cross the blood brain bather (BBB). In order to measure the levels of compounds of formula (I) in plasma and brain, mice (C57BL6/J, males of 8-week aged) were dosed with an intravenous administration (1 mg/kg) and two oral administrations (20 mg/kg and 200 mg/kg) of the different compounds. Each compound was solved in appropriate excipients. In the case of oral administration, compound was administered by means of an oral gavage coupled to a syringe. In the intravenous administration animals, the test item was administered by a single injection with a syringe coupled to a 30 G needle.
Two animals were sacrificed (according to internal SOPs and following animal handling and welfare guidelines) at each selected extraction times (i.e. 30 min, 1 h, 2 h, 4 h, 6 h, 8 h and 24 hours after administration), and from each animal, both brain and blood samples were obtained. Plasma was extracted by centrifugation of the blood samples. Each sample time represents two male mice from which samples were obtained.
The method for the analysis of plasma and brain samples involved isolation of the analyte from the biological matrix by protein precipitation or solid-phase extraction followed by analysis using LC-MS/MS. Limits of quantification for these compounds were in the order of 2-10 ng/mL. The software Winnonlin professional version 5.2 was used for the calculation of pharmacokinetic parameters.

Results

In the following tables, the abbreviations have the meaning indicated below:
AUC=Area under the curve

T_1/2=Half-life

T_max=the time after administration of a drug when the maximum plasma concentration is reached; when the rate of absorption equals the rate of elimination
C_max=maximum plasma concentration of the drug
V. Adm. and Vol. Adm.=volume of administration
1. Group 1-2 mg/kg Intravenous Route

TABLE 7

			C_max
	V. Adm.	Dose	Plasma
Compound No.	(ml/Kg)	(mg/Kg)	(ng/ml)	T_1/2(h)	T_max	AUC

Compound 4	2	1.00	78.70	0.22	0.25	36
Compound 7	1	1.20	104.2	4.47	1.00	319
Compound 8	2	1.00	689.5	1.11	0.25	243.7
Compound 10	2	2.00	136.50	8.10	0.08	148

TABLE 8

	Dose	C_max
Compound	(mg/	Brain	T_1/2				%
No.	Kg)	(ng/g)	(h)	T_max	AUC	% C_max	AUC

Compound 4	1.00	104.40	0.39	0.25	45.80	132.66	127.22
Compound 7	1.20	386.10	NC	0.08	330.50	370.54	103.61
Compound 8	1.00	36.10	0.18	0.25	10.70	5.24	4.39
Compound 10	2.00	18.7	2.60	0.08	33.90	13.70	22.91

2. Group 20 mg/kg Oral Route

TABLE 9

		C_max
Compound	V. Adm.	Plasma				Bio-
No.	(ml/Kg)	(ng/ml)	T_1/2(h)	T_max	AUC	availability

Compound
4	4	20.75	0.30	0.25	7.24	1.01
Compound 7	4	106.50	1.66	0.30	378.10	7.11
Compound 8	4	396.40	3.90	0.25	325.20	6.67
Compound 10	4	149.20	4.00	1.00	184.40	12.46

TABLE 10

		C_max
Compound	Dose	Brain	T_1/2
No.	(mg/g)	(ng/g)	(h)	T_max	AUC	% C_max	% AUC

Compound	20	15.40	0.66	0.25	20.00	74.22	276.24
4
Compound	20	19.62	0.73	4.00	23.90	41.66	27.76
7
Compound	20	24.60	1.80	0.25	13.60	6.21	4.18
8
Compound	20	13.07	NC	1.00	22.00	8.76	11.93
10

3. Group 200 mg/kg Oral Route

TABLE 11

	Vol.	C_max
Compound	Adm.	Plasma	T_1/2			Bio-
No.	(ml/Kg)	(ng/ml)	(h)	T_max	AUC	availability

Compound
4	4	930.70	0.92	0.50	1375.70	19.11
Compound 7	4	1205.20	—	0.50	1696.80	3.19
Compound 8	—	—	—	—	—	—
Compound 10	4	3950.70	3.79	0.50	11478.90	77.56

TABLE 12

Com-		C_max
pound	Dose	Brain	T_1/2			%	%
No.	(mg/g)	(ng/g)	(h)	T_max	AUC	C_max	AUC

Com-	200	1394.40	0.94	0.50	1537.90	149.82	111.79
pound 4
Com-	200	—	—	—	—	—	—
pound 7
Com-	200	—	—	—	—	—	—
pound 8
Com-	200	7751.80	—	2.00	95478.00	196.21	831.77
pound 10

Conclusions

Regarding the results shown in previous tables (7-12), all tested compounds of formula (I) are able to cross the blood brain barrier because they are detected in brain. Oral bioavailability is in the range between 7 and 10% at low dose, and is increased significantly at the high concentration.

Example 15

Evaluation of the Chelating Ability of Some Compounds of Formula (I) with Fe(II)

The assays carried out in presence of the chelating ligands Compound 4, Compound 7, Compound 8 and compound 10 demonstrated that the ligands are able to complex the Fe (II), as the spectrum obtained for the mixture of each ligand and the iron differs from the sum of the respective individual spectra (see FIGS. 2, 3, 4 and 5).

Example 16

a) Evaluation of the Chelating Ability of Some Compounds of Formula (I) with Fe (III)

The assays carried out in presence of Fe (III) have demonstrated that none of the compounds of formula (I) were able to complex this metal, because no change in the absorbance spectra of the ligand in presence of Fe (III) is observed; as shown in FIG. 1 for compounds 4, 7, 8 and 10. Only one line is observed, as the spectra are overlapping (see FIG. 1).

b) Evaluation of the Chelating Ability of Some Compounds of Formula (I) with Cu (II)

The assays carried out in presence of the chelating ligands Compound 4, Compound 7 and Compound 8 demonstrated that none of the ligands are able to complex the Cu (II), as the spectrum obtained for the mixture of each ligand and the copper is coincident with the sum of the respective individual spectra (see FIGS. 6 and 7).

c) Evaluation of the Chelating Ability of Some Compounds of Formula (I) with Zn (II)

All of compounds 4, 7, 8, and 10 complexed with Zn(II) to an extent, but having a relatively low formation constant and a relatively high dissociation grade, thus showing that the complexes are not too stable (see FIGS. 8, 9,10 and 11).

Summary of the Results

In the formation of complexes between metallic ions and quelatns, the higher a formation constant and the lower the dissociation grade, the more stable is the complex. Therefore, it may be observed that the compounds of formula (I) have a high affinity to Fe (II) in comparison to the rest of metallic ions tested.

TABLE 13

							ε
	Ligand						approx.
	(compound	Expecting			Dissociation	Formation	(l mol⁻¹
Metal	no.)	time	pH	Stoichiometry	grade	constant	cm⁻¹)

Cu(II)	10	2 h	7.4	1:1 (ML)	3.8 ± 0.4	4.4 ± 0.6 · 10⁶	400
						(l/mol)
Zn(II)	4	24 h	7.4	1:1 (ML)	46 ± 7	2.2 ± 0.6 · 10⁴	1000
						(l/mol)
	7	24 h	7.4	1:2 (ML₂)	13.4 ± 0.7	2.2 ± 0.6 · 10¹⁰	840
						(l²/mol²)
	8	4 h	7.4	1:2 (ML₂)	7.7 ± 0.6	1.4 ± 0.6 · 10¹¹	7100
	10	4 h	7.4	1:2 (ML₂)	3.7 ± 0.6	1.7 ± 0.4 · 10¹³	9400
						(l²/mol²)
Fe(II)	4	30 min	8*	1:3 (ML₃)	0.147 ±	8.2 ± 0.5 · 10¹²	1.8 ·
					0.002		10³
	7	60 min	8*	1:3 (ML₃)	0.023 ±	2.0 ± 0.6 · 10¹⁵	2.8 ·
					0.002		10²
	8	Immediate	7.4	1:3 (ML₃)	0.022 ±	4.0 ± 1.3 · 10¹⁷	1.6 ·
					0.006		10³
	10	Immediate	7.4	1:3 (ML₃)	0.019 ±	5.0 ± 1.0 · 10¹⁷	6.7 ·
					0.004		10³

Claims

What is claimed is:

1. A method of treating or preventing a neurodegenerative or hematological disease or condition, which method comprises administering to a patient a therapeutically effective amount, for such treatment or prevention, of at least one compound of formula (I):

wherein R¹is selected from —S—R³, —O—R⁴and halogen;

R⁷is selected from —CH═N—OR⁸or —CHO;

R³and R⁴are independently selected from the group consisting of C₁-C₆alkyl, C₆-C₁₅aryl and heteroaryl, each of which is optionally substituted by C₁-C₆alkyl, C₆-C₁₅aryl, halogen, —(C═O)NR⁵R⁶, —(C═O)OR⁵, C₁-C₆alkoxy and/or —NR⁵R⁶,

R⁵and R⁶being independently selected from hydrogen and C₁-C₆alkyl,

R⁸is selected from hydrogen and C₁-C₆alkyl;

or a salt or solvate or stereoisomer or tautomer thereof.

2. The method according to claim 1, wherein:

R¹is selected from —S—R³, —O—R⁴and halogen;

R⁷is selected from —CH═N—OR⁸or —CHO;

R³and R⁴are independently a C₁-C₆alkyl, each of which is optionally substituted by C₁-C₆alkoxy and/or —NR⁵R⁶;

R⁵and R⁶are independently selected from hydrogen and C₁-C₆alkyl; and

R⁸is selected from hydrogen and C₁-C₆alkyl.

3. The method according to claim 1, wherein the neurodegenerative disease is selected from the group consisting of Alzheimer's Disease, Parkinson's Disease, amyotrophic lateral sclerosis (ALS), schizophrenia, Huntington's Disease, brain injuries, stroke, ischemia, multiple sclerosis, epilepsy, Friedreich's Ataxia, spongiform encephalopathies, amyloidosis, vascular dementia, tauopathies, progressive supranuclear palsy, corticobasal degeneration, frontotemporal lobular degeneration, subacute sclerosing panencephalitic parkinsonism, postencephalitic parkinsonism, pugilistic encephalitis, guam parkinsonism-dementia complex, Pick's disease, frontotemporal dementia, AIDS associated dementia, multiple sclerosis, mood disorders, depression, schizophrenia, and bipolar disorders.

4. The method according to claim 1, wherein the hematological disease is selected from the group consisting of thalassaemia, anaemia, aplastic anaemia, Diamond-Blackfan anemia, sickle cell disease, hematologic disorders requiring periodic red cell transfusions, myelodysplastic syndrome, iron-induced cardiac dysfunction, iron-induced heart failure, and diabetes.

5. The method according to claim 2, wherein the hematological disease is selected from the group consisting of thalassaemia, anaemia, aplastic anaemia, Diamond-Blackfan anemia, sickle cell disease, hematologic disorders requiring periodic red cell transfusions, myelodysplastic syndrome, iron-induced cardiac dysfunction, iron-induced heart failure, and diabetes.

6. The method according to claim 1, wherein R⁷is —CH═N—OR⁸.

7. The method according to claim 5, wherein R⁸is hydrogen.

8. The method according to claim 1, wherein R¹is —S—R³.

9. The method according to claim 8, wherein R³is selected from methyl, ethyl, propyl, isopropyl and heteroaryl, said heteroaryl being optionally substituted by C₁-C₆alkyl, C₆-C₁₅aryl, halogen, —(C═O)NR⁵R⁶, —(C═O)OR⁵, C₁-C₆alkoxy and/or —NR⁵R⁶.

10. The method according to claim 9, wherein the heteroaryl group is substituted by C₁-C₃alkyl.

11. The method according to claim 1, wherein R¹is —O—R⁴.

12. The method according to claim 11, wherein R⁴is selected from methyl, ethyl, and ethyl substituted by an amine of formula —NR⁵R⁶or methoxy, wherein each of R⁵and R⁶is independently selected from hydrogen and C₁-C₆alkyl.

13. The method according to claim 12, wherein the amine is primary or tertiary.

14. The method according to claim 13, wherein the tertiary amine is diethyl-amine.

15. The method according to claim 1, wherein the double bond of the oxime group —CH═NOR⁸presents an E conformation.

16. The method according to claim 1, wherein R¹is chloro.

17. The method according to claim 1, wherein R³is a C₁-C₃alkyl group substituted by —(C═O)NR⁵R⁶or —(C═O)OR⁵.

18. The method according to claim 1, wherein R⁷is —CH═N—OR⁸and R¹is —S—R³or —O—R⁴.

19. The method according to claim 1, wherein the compound of formula (I) is selected from the following compounds:

4-Methoxy-[1,10]phenanthroline-2-carbaldehyde oxime

4-Chloro-[1,10]phenanthroline-2-carbaldehyde oxime

4-Chloro-[1,10]phenanthroline-2-carbaldehyde

4-Methylsulfanyl-[1,10]phenanthroline-2-carbaldehyde oxime

4-Propylsulfanyl-[1,10]phenanthroline-2-carbaldehyde oxime

4-Ethoxy-[1,10]phenanthroline-2-carbaldehyde oxime

4-Isopropylsulfanyl-[1,10]phenanthroline-2-carbaldehyde oxime

4-(2-Methoxy-ethoxy)-[1,10]phenanthroline-2-carbaldehyde oxime

4-(2-Amino-ethoxy)-[1,10]phenanthroline-2-carbaldehyde oxime

4-(2-Diethylamino-ethoxy)-[1,10]phenanthroline-2-carbaldehyde oxime

4-(2-Methoxy-ethylsulfanyl)-[1,10]phenanthroline-2-carbaldehyde oxime

2-[2-(Hydroxyimino-methyl)-[1,10]phenanthrolin-4-ylsulfanyl]-N,N-dimethyl-acetamide

4-(2,2,2-Trifluoro-ethylsulfanyl)-[1,10]phenanthroline-2-carbaldehyde oxime

[2-(Hydroxyimino-methyl)-[1,10]phenanthrolin-4-ylsulfanyl]-acetic acid methyl ester

4-(Thiazol-2-ylsulfanyl)-[1,10]phenanthroline-2-carbaldehyde oxime

[2-(Hydroxyimino-methyl)-[1,10]phenanthrolin-4-ylsulfanyl]-acetic acid

4-(5-Methyl-thiazol-2-ylsulfanyl)-[1,10]phenanthroline-2-carbaldehyde oxime

4-(5-Methyl-[1,3,4]thiadiazol-2-ylsulfanyl)-[1,10]phenanthroline-2-carbaldehyde oxime

4-([1,3,4]Thiadiazol-2-ylsulfanyl)-[1,10]phenanthroline-2-carbaldehyde oxime

4-Methylsulfanyl-[1,10]phenanthroline-2-carbaldehyde

4-Propylsulfanyl-[1,10]phenanthroline-2-carbaldehyde

4-Propylsulfanyl-[1,10]phenanthroline-2-carbaldehyde oxime

4-Ethoxy-[1,10]phenanthroline-2-carbaldehyde

4-Isopropylsulfanyl-[1,10]phenanthroline-2-carbaldehyde

4-(2-Methoxy-ethoxy)-[1,10]phenanthroline-2-carbaldehyde

4-(2-Diethylamino-ethoxy)-[1,10]phenanthroline-2-carbaldehyde

or salts, solvates, stereoisomers or tautomers thereof.